Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GRETEL TRULLENQUE

Allopathic & Osteopathic Physicians Family Medicine

NPI
1720076144
CMS profile
32746
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$259.48

14 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $259.48 14

By paying entity

PY2021 · entire year · sorted by reported total

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GRETEL TRULLENQUE

NPI 1720076144 · CMS profile ID 32746

Allopathic & Osteopathic Physicians / Family Medicine

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1720076144?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GRETEL TRULLENQUE, NPI 1720076144, CMS profile ID 32746. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1720076144?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). GRETEL TRULLENQUE, NPI 1720076144, CMS profile ID 32746. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1720076144?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
GRETEL TRULLENQUE, NPI 1720076144, CMS profile ID 32746, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1720076144?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

14 matching records · $259.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 14 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–14 of 14.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $22.2705/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788606133 CMS
AbbVie Inc. $16.1004/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796174807 CMS
Janssen Pharmaceuticals, Inc $19.9803/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788606137 CMS
Janssen Pharmaceuticals, Inc $17.8502/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788606135 CMS
PFIZER INC. $17.1402/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833592377 CMS
Novo Nordisk Inc $24.1702/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810930157 CMS
GlaxoSmithKline, LLC. $20.3602/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803009219 CMS
Merck Sharp & Dohme Corporation $16.6902/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848464081 CMS
AbbVie Inc. $14.3301/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796174805 CMS
Lilly USA, LLC $20.0801/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819179339 CMS
Lilly USA, LLC $16.2601/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818560599 CMS
Kowa Pharmaceuticals America, Inc. $17.7001/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805594203 CMS
Amneal Pharmaceuticals LLC $16.4901/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829682879 CMS
Novo Nordisk Inc $20.0601/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811126305 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,374.49 69
PY2020 $1,355.75 79
PY2021 $259.48 14
PY2022 $192.27 9
PY2023 $2,004.82 9
PY2024 $1,983.09 17
PY2025 $1,220.64 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,629,687.56 10
PY2024 Principal investigator $1,001,480.43 22
PY2023 Principal investigator $393,727.30 31
PY2022 Principal investigator $743,619.78 33
PY2021 Principal investigator $102,847.74 117
PY2020 Principal investigator $1,098,095.92 216
PY2019 Principal investigator $335,867.48 106

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

216 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AbbVie Inc. $10,758.20 12/30/2020 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
M16-100 No dispute reported 06/30/2026 721202539
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $3,050.00 12/09/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713695553
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $3,050.00 12/09/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713695555
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,792.00 12/09/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713695557
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,792.00 12/09/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713695561
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,792.00 12/09/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713695573
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,792.00 12/09/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713695587
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,792.00 12/09/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713695591
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,792.00 12/09/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713695595
Principal investigator 1 AbbVie Inc. $2,525.10 12/01/2020 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
M16-100 No dispute reported 06/30/2026 721197959
Principal investigator 1 Janssen Research & Development, LLC $11,625.00 11/16/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498977
Principal investigator 1 Janssen Research & Development, LLC $11,625.00 11/16/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498981
Principal investigator 1 Janssen Research & Development, LLC $11,625.00 11/16/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498983
Principal investigator 1 Janssen Research & Development, LLC $17,625.00 11/16/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498987
Principal investigator 1 Janssen Research & Development, LLC $12,406.25 11/16/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498991
Principal investigator 1 Janssen Research & Development, LLC $10,800.00 11/16/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499201
Principal investigator 1 Janssen Research & Development, LLC $9,431.25 11/16/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499203
Principal investigator 1 Incyte Corporation $4,423.00 11/03/2020 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 744320563
Principal investigator 1 AbbVie Inc. $755.80 10/29/2020 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
M16-100 No dispute reported 06/30/2026 721192725
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,258.00 10/29/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713694145
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,258.00 10/09/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713691769
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,258.00 10/09/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713691773
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,258.00 10/09/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713691793
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,258.00 10/09/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713691807
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,258.00 10/09/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713691813
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,994.00 10/09/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713691827
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,258.00 10/09/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713691829
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,994.00 10/09/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713691833
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,994.00 10/09/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713691835
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,258.00 10/09/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713691841
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,258.00 10/09/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713691843
Principal investigator 1 Janssen Research & Development, LLC $15,225.00 10/09/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498923
Principal investigator 1 Janssen Research & Development, LLC $11,625.00 10/09/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498927
Principal investigator 1 Janssen Research & Development, LLC $11,625.00 10/09/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498931
Principal investigator 1 Janssen Research & Development, LLC $11,625.00 10/09/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498935
Principal investigator 1 Janssen Research & Development, LLC $16,725.00 10/09/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498937
Principal investigator 1 Janssen Research & Development, LLC $11,625.00 10/09/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498941
Principal investigator 1 Janssen Research & Development, LLC $11,625.00 10/09/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498946
Principal investigator 1 Janssen Research & Development, LLC $11,625.00 10/09/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498950
Principal investigator 1 Janssen Research & Development, LLC $15,225.00 10/09/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498953
Principal investigator 1 Janssen Research & Development, LLC $11,625.00 10/09/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498957
Principal investigator 1 Janssen Research & Development, LLC $12,225.00 10/09/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498959
Principal investigator 1 Janssen Research & Development, LLC $11,625.00 10/09/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498961
Principal investigator 1 Janssen Research & Development, LLC $21,600.00 10/09/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498965
Principal investigator 1 Janssen Research & Development, LLC $11,625.00 10/09/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498969
Principal investigator 1 Janssen Research & Development, LLC $11,625.00 10/09/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498973
Principal investigator 1 Janssen Research & Development, LLC $6,112.50 10/09/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499147
Principal investigator 1 Janssen Research & Development, LLC $5,812.50 10/09/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499151
Principal investigator 1 Janssen Research & Development, LLC $9,375.00 10/09/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499155
Principal investigator 1 Janssen Research & Development, LLC $5,812.50 10/09/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499158
Principal investigator 1 Janssen Research & Development, LLC $5,812.50 10/09/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499161
Principal investigator 1 Janssen Research & Development, LLC $5,812.50 10/09/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499165
Principal investigator 1 Janssen Research & Development, LLC $10,125.00 10/09/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499169
Principal investigator 1 Janssen Research & Development, LLC $5,812.50 10/09/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499171
Principal investigator 1 Janssen Research & Development, LLC $5,812.50 10/09/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499175
Principal investigator 1 Janssen Research & Development, LLC $5,812.50 10/09/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499177
Principal investigator 1 Janssen Research & Development, LLC $9,375.00 10/09/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499181
Principal investigator 1 Janssen Research & Development, LLC $5,812.50 10/09/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499185
Principal investigator 1 Janssen Research & Development, LLC $5,812.50 10/09/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499189
Principal investigator 1 Janssen Research & Development, LLC $5,812.50 10/09/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499193
Principal investigator 1 Janssen Research & Development, LLC $10,618.75 10/09/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499197
Principal investigator 1 Eli Lilly and Company $21,650.80 10/08/2020 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 728738281
Principal investigator 1 AbbVie Inc. $987.50 09/30/2020 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
M16-100 No dispute reported 06/30/2026 721187965
Principal investigator 1 Janssen Research & Development, LLC $16,425.00 09/23/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498915
Principal investigator 1 Janssen Research & Development, LLC $11,625.00 09/23/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498919
Principal investigator 1 Janssen Research & Development, LLC $12,787.50 09/23/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499131
Principal investigator 1 Janssen Research & Development, LLC $1,937.50 09/23/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499133
Principal investigator 1 Janssen Research & Development, LLC $1,937.50 09/23/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499137
Principal investigator 1 Janssen Research & Development, LLC $1,937.50 09/23/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499141
Principal investigator 1 Janssen Research & Development, LLC $10,875.00 09/23/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499143
Principal investigator 1 AbbVie Inc. $63.70 08/28/2020 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
M16-100 No dispute reported 06/30/2026 721182825
Principal investigator 1 Janssen Research & Development, LLC $1,937.50 08/28/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498887
Principal investigator 1 Janssen Research & Development, LLC $1,937.50 08/28/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498889
Principal investigator 1 Janssen Research & Development, LLC $1,937.50 08/28/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498893
Principal investigator 1 Janssen Research & Development, LLC $1,937.50 08/28/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498897
Principal investigator 1 Janssen Research & Development, LLC $1,937.50 08/28/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498901
Principal investigator 1 Janssen Research & Development, LLC $1,937.50 08/28/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498905
Principal investigator 1 Janssen Research & Development, LLC $11,625.00 08/28/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498909
Principal investigator 1 Janssen Research & Development, LLC $11,625.00 08/28/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498913
Principal investigator 1 Janssen Research & Development, LLC $2,037.50 08/28/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499107
Principal investigator 1 Janssen Research & Development, LLC $1,937.50 08/28/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499109
Principal investigator 1 Janssen Research & Development, LLC $2,187.50 08/28/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499113
Principal investigator 1 Janssen Research & Development, LLC $12,312.50 08/28/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499117
Principal investigator 1 Janssen Research & Development, LLC $5,812.50 08/28/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499119
Principal investigator 1 Janssen Research & Development, LLC $5,812.50 08/28/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499123
Principal investigator 1 Janssen Research & Development, LLC $5,812.50 08/28/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499127
Principal investigator 1 Janssen Research & Development, LLC $1,937.50 08/21/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498819
Principal investigator 1 Janssen Research & Development, LLC $1,937.50 08/21/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498823
Principal investigator 1 Janssen Research & Development, LLC $1,937.50 08/21/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498827
Principal investigator 1 Janssen Research & Development, LLC $1,937.50 08/21/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498831
Principal investigator 1 Janssen Research & Development, LLC $1,937.50 08/21/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498835
Principal investigator 1 Janssen Research & Development, LLC $1,937.50 08/21/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498839
Principal investigator 1 Janssen Research & Development, LLC $2,787.50 08/21/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498843
Principal investigator 1 Janssen Research & Development, LLC $2,787.50 08/21/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498847
Principal investigator 1 Janssen Research & Development, LLC $2,787.50 08/21/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498851
Principal investigator 1 Janssen Research & Development, LLC $2,787.50 08/21/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498855
Principal investigator 1 Janssen Research & Development, LLC $2,787.50 08/21/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498859
Principal investigator 1 Janssen Research & Development, LLC $2,787.50 08/21/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498863
Principal investigator 1 Janssen Research & Development, LLC $2,125.00 08/21/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499077
Principal investigator 1 Janssen Research & Development, LLC $1,937.50 08/21/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499081
Principal investigator 1 Janssen Research & Development, LLC $2,125.00 08/21/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499085
Principal investigator 1 Janssen Research & Development, LLC $3,587.50 08/21/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499089
Principal investigator 1 Janssen Research & Development, LLC $3,857.50 08/21/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499093
Principal investigator 1 Janssen Research & Development, LLC $3,587.50 08/21/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499096
Principal investigator 1 Janssen Research & Development, LLC $2,125.00 08/21/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499099
Principal investigator 1 Incyte Corporation $1,199.25 08/03/2020 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis No dispute reported 06/30/2026 744320561
Principal investigator 1 AbbVie Inc. $4,519.40 07/30/2020 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
M16-100 No dispute reported 06/30/2026 721177511
Principal investigator 1 CIPLA USA INC. $545.71 07/23/2020 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A MULTICENTER, RANDOMIZED, PARALLEL-GROUP, PLACEBO-CONTROLLED, 4-WEEK CLINICAL ENDPOINT BIOEQUIVALENCE STUDY COMPARING FLUTICASONE PROPIONATE/SALMETEROL 100/50 MICRO GM INHALATION POWDER WITH ADVAIR DISKUS 100/50 MICRO GM IN ASTHMA PATIENTS No dispute reported 06/30/2026 751144835
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 07/17/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498773
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 07/17/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498777
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 07/17/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498779
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 07/17/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498783
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 07/17/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498787
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 07/17/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498791
Principal investigator 1 Janssen Research & Development, LLC $2,537.50 07/17/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498795
Principal investigator 1 Janssen Research & Development, LLC $2,537.50 07/17/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498801
Principal investigator 1 Janssen Research & Development, LLC $2,537.50 07/17/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498803
Principal investigator 1 Janssen Research & Development, LLC $2,537.50 07/17/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498807
Principal investigator 1 Janssen Research & Development, LLC $2,537.50 07/17/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498811
Principal investigator 1 Janssen Research & Development, LLC $2,537.50 07/17/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498815
Principal investigator 1 Janssen Research & Development, LLC $3,700.00 07/17/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499053
Principal investigator 1 Janssen Research & Development, LLC $16,200.00 07/17/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499057
Principal investigator 1 Janssen Research & Development, LLC $12,962.50 07/17/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499061
Principal investigator 1 Janssen Research & Development, LLC $5,575.00 07/17/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499065
Principal investigator 1 Janssen Research & Development, LLC $3,387.50 07/17/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499069
Principal investigator 1 Janssen Research & Development, LLC $1,937.50 07/17/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499073
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,258.00 07/13/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713686129
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,258.00 07/13/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713686161
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,258.00 07/13/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713686173
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,258.00 07/13/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713686185
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,258.00 07/13/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713686219
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,994.00 07/13/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713686223
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,258.00 07/13/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713686245
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,994.00 07/13/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713686249
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,258.00 07/13/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713686287
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,258.00 07/13/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713686311
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,258.00 07/13/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713686349
Principal investigator 1 Incyte Corporation $4,348.89 07/01/2020 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis No dispute reported 06/30/2026 744320557
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $5,375.00 06/30/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 713685863
Principal investigator 1 Janssen Research & Development, LLC $12,000.00 06/19/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498765
Principal investigator 1 Janssen Research & Development, LLC $16,425.00 06/19/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498769
Principal investigator 1 Janssen Research & Development, LLC $28,950.00 06/19/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499049
Principal investigator 1 Incyte Corporation $4,906.20 06/12/2020 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis No dispute reported 06/30/2026 744320555
Principal investigator 1 Janssen Research & Development, LLC $6,075.00 06/05/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498755
Principal investigator 1 Janssen Research & Development, LLC $13,000.00 06/05/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498759
Principal investigator 1 Janssen Research & Development, LLC $13,000.00 06/05/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498761
Principal investigator 1 Janssen Research & Development, LLC $8,850.00 06/05/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499047
Principal investigator 1 AbbVie Inc. $822.10 05/28/2020 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
M16-100 No dispute reported 06/30/2026 721167759
Principal investigator 1 Incyte Corporation $30.40 05/08/2020 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis No dispute reported 06/30/2026 744320553
Principal investigator 1 Janssen Research & Development, LLC $11,500.00 05/06/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498871
Principal investigator 1 Janssen Research & Development, LLC $2,950.00 05/06/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498875
Principal investigator 1 Janssen Research & Development, LLC $2,600.00 05/06/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498879
Principal investigator 1 Janssen Research & Development, LLC $5,750.00 05/06/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498883
Principal investigator 1 Janssen Research & Development, LLC $4,000.00 05/06/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499033
Principal investigator 1 Janssen Research & Development, LLC $19,662.50 05/06/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499037
Principal investigator 1 Janssen Research & Development, LLC $14,225.00 05/06/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499041
Principal investigator 1 Janssen Research & Development, LLC $14,300.00 05/06/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499045
Principal investigator 1 Janssen Research & Development, LLC $1,937.50 05/06/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499103
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,167.00 05/04/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 713682225
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,167.00 05/04/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 713682243
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,167.00 05/04/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 713682259
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $4,161.00 05/04/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 713682261
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,167.00 05/04/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 713682279
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,792.00 05/04/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 713682295
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $3,425.00 05/04/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 713682297
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,167.00 05/04/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 713682299
Principal investigator 1 AbbVie Inc. $1,644.20 04/30/2020 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
M16-100 No dispute reported 06/30/2026 721163145
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,994.00 04/28/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713681811
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,258.00 04/28/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713681827
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,994.00 04/28/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713681839
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,258.00 04/28/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713681929
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,994.00 04/28/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713681949
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,994.00 04/28/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713681955
Principal investigator 1 Janssen Research & Development, LLC $2,600.00 04/17/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498747
Principal investigator 1 Janssen Research & Development, LLC $9,112.50 04/17/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498751
Principal investigator 1 Incyte Corporation $13,392.42 04/02/2020 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis No dispute reported 06/30/2026 744320551
Principal investigator 1 AbbVie Inc. $1,889.20 03/30/2020 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
M16-100 No dispute reported 06/30/2026 721157777
Principal investigator 1 Janssen Research & Development, LLC $12,150.00 03/25/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498867
Principal investigator 1 Janssen Research & Development, LLC $3,575.00 03/24/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499003
Principal investigator 1 Janssen Research & Development, LLC $3,450.00 03/24/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499007
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 03/24/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499011
Principal investigator 1 Janssen Research & Development, LLC $3,450.00 03/24/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499013
Principal investigator 1 Janssen Research & Development, LLC $1,937.50 03/24/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499015
Principal investigator 1 Janssen Research & Development, LLC $3,387.50 03/24/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499019
Principal investigator 1 Janssen Research & Development, LLC $14,300.00 03/24/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499023
Principal investigator 1 Janssen Research & Development, LLC $14,900.00 03/24/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499025
Principal investigator 1 Janssen Research & Development, LLC $10,350.00 03/24/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719499029
Principal investigator 1 AbbVie Inc. $453.00 03/10/2020 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
M16-100 No dispute reported 06/30/2026 721155221
Principal investigator 1 Incyte Corporation $4,423.00 03/03/2020 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis No dispute reported 06/30/2026 744320559
Principal investigator 1 Janssen Research & Development, LLC $500.00 02/19/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498740
Principal investigator 1 Janssen Research & Development, LLC $2,400.00 02/19/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 719498743
Principal investigator 1 Janssen Research & Development, LLC $500.00 02/19/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719498995
Principal investigator 1 Janssen Research & Development, LLC $2,400.00 02/19/2020 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719498999
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,994.00 02/17/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713677595
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,994.00 02/17/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713677597
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,994.00 02/17/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713677601
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,258.00 02/17/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713677603
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,258.00 02/17/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713677607
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,258.00 02/17/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713677613
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,994.00 02/17/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713677615
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,994.00 02/17/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713677617
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,258.00 02/14/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 713677503
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,994.00 02/14/2020 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 713677505
Principal investigator 1 DERMIRA, INC. $3,000.00 02/13/2020 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 736908635
Principal investigator 1 DERMIRA, INC. $1,500.00 02/13/2020 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 736908639
Principal investigator 1 DERMIRA, INC. $1,500.00 02/13/2020 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 736909279
Principal investigator 1 DERMIRA, INC. $650.00 02/13/2020 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 736909295
Principal investigator 1 Incyte Corporation $30.40 02/10/2020 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis No dispute reported 06/30/2026 744320537
Principal investigator 1 Incyte Corporation $23.40 02/10/2020 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis No dispute reported 06/30/2026 744320539
Principal investigator 1 Incyte Corporation $30.40 02/10/2020 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis No dispute reported 06/30/2026 744320541
Principal investigator 1 Incyte Corporation $30.40 02/10/2020 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis No dispute reported 06/30/2026 744320543
Principal investigator 1 Incyte Corporation $30.40 02/10/2020 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis No dispute reported 06/30/2026 744320545
Principal investigator 1 Incyte Corporation $30.40 02/10/2020 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis No dispute reported 06/30/2026 744320547
Principal investigator 1 Incyte Corporation $23.40 02/10/2020 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis No dispute reported 06/30/2026 744320549
Principal investigator 1 AbbVie Inc. $6,863.00 01/30/2020 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
M16-100 No dispute reported 06/30/2026 721147761
Principal investigator 1 CIPLA USA INC. $7,153.00 01/21/2020 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
U-FS-MU-AS3120 No dispute reported 06/30/2026 751145455